drugset / Trial / NCT07045311
JS207 Combination Therapy in Triple-negative Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
Timeline
- Start
- 2025-09-17
- Primary completion
- 2028-03-22
- Completion
- 2029-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW2821 | Monoclonal antibody | 1.25 mg/kg | Intravenous |
| Subject | JS207 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |